Marksans Pharma board to meet for Q2 earnings approval

Marksans Pharma Ltd. has announced that its board of directors will convene on Thursday, November 13, 2025. The primary agenda for this meeting is to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025. These results will encompass both standalone and consolidated financial statements.

In accordance with SEBI regulations, the trading window for Marksans Pharma shares has been closed for designated persons and their immediate relatives. This closure commenced on October 1, 2025, and will remain in effect until 48 hours after the announcement of the financial results, specifically up to November 15, 2025.

Further details regarding the board meeting will be accessible on the company's website, as well as on the websites of BSE Limited and National Stock Exchange of India Limited.